Oncology

  • 5 April 2019
    News

    NICE recommends BMS’ Opdivo-Yervoy combination for RCC

    Bristol-Myers Squibb (BMS) has announced that the National Institute of Health and Care Excellence (NICE) has recommends Opdivo (nivolumab) and Yervoy (ipilimumab) combination therapy to treat National Health Service (NHS)...

Go Top